about
Adenovirus vectors for gene therapy, vaccination and cancer gene therapyHAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model.Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamstersImmune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic.Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster modelTumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death proteinTranscription factor TFIID is a direct functional target of the adenovirus E1A transcription-repression domain.Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters.Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamstersSTAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral ControlTranscriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters.New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.A fully replication-competent adenovirus vector with enhanced oncolytic propertiesImmunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.New drug on the horizon for treating adenovirusSpecific recruitment of γδ regulatory T cells in human breast cancer.Oncolytic (replication-competent) adenoviruses as anticancer agents.Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model.Combination therapy with brincidofovir and valganciclovir against species C adenovirus infection in the immunosuppressed Syrian hamster model allows for substantial reduction of dose for both compounds.Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.Cotton rat tumor model for the evaluation of oncolytic adenoviruses.Adenovirus immunoregulatory E3 proteins prolong transplants of human cells in immunocompetent mice.HEK? No!Anti-adenoviral Artificial MicroRNAs Expressed from AAV9 Vectors Inhibit Human Adenovirus Infection in Immunosuppressed Syrian Hamsters.Characterization of an N-Terminal Non-Core Domain of RAG1 Gene Disrupted Syrian Hamster Model Generated by CRISPR Cas9.Male Syrian hamsters are more susceptible to intravenous infection with species C human adenoviruses than are females.A multitasking oncolytic adenovirus vectorOverexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirusConstruction and characterization of E1-minus replication-defective adenovirus vectors that express E3 proteins from the E1 regionAdenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc)
P50
Q27001601-166B54C3-0805-4D3A-884F-26486EFB908EQ32183133-40EAF495-AD9C-4CCF-9082-4DDA0806C639Q33580223-66493875-F651-45C1-B224-D2BAD7E27C53Q33711437-CFE5D035-4595-4A43-B909-13724A491386Q33713048-0E5618B9-412C-4022-B013-F9B714E4FDAAQ33807026-F14493DD-A531-4D8A-B905-3000CF468D58Q33835898-3AE2F687-DBCA-41CC-8702-47C69FA4C849Q34597872-3399E41F-4B1E-4C80-ACCA-C636B052F467Q35232836-D15E30F4-911F-4C1E-A33B-560B9F4812EBQ35751170-3BD77928-F8A4-44A7-A85A-B5CB9AA8BAAFQ36202563-50A321C2-4E6B-4306-8105-AF15FEA45526Q36209172-30867134-3097-45F9-B514-C385E7271DB6Q36209205-252B976E-F388-4383-A745-D49DDF272B8CQ36221367-BA1E3DAC-215A-4D2A-8396-974FCE8B0D4BQ36221386-932CDF60-4DD1-4C67-92C0-4F4C511889EFQ36900283-1E5C1A6B-1EED-4347-8AAA-B06E38A69DE8Q37238831-14C7BFCB-40DF-44EA-8846-96A79150CC9CQ37687415-33627202-1601-43CB-8E56-2D2A32C8752AQ38934424-3F3403B9-CC3B-4450-B0D1-23AAF9D80B6EQ40076261-378B302D-15D8-435F-9A14-BE81333AB0DEQ40322147-96F76C3B-6448-45E2-BE04-5AE7FEFE9127Q40460003-1D51B0E0-0983-467E-AE78-52CE65042F66Q40463873-BE609A07-DE4A-44B1-A32E-722244CD4E4CQ40730206-C44748C5-D5B3-4BAD-BE95-E1A77EB005E8Q41191009-A79A055E-FA61-4619-879E-C620FB07B83CQ54219127-07EA365F-2C6A-4033-91A8-533A932D63A3Q54317681-94B10823-074D-411E-AC91-D097D86F9FA5Q64377757-B7BE6FB6-7619-4403-937B-86DBAB856966Q64378041-72ADE8C5-9246-477C-A457-16D796CCD182Q64378435-25F1FD36-29CE-4C80-8B5E-57C790BBAA05Q64378610-D324DF10-482D-473E-ABFA-1557C502033F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
K Toth
@ast
K Toth
@en
K Toth
@es
K Toth
@nl
type
label
K Toth
@ast
K Toth
@en
K Toth
@es
K Toth
@nl
prefLabel
K Toth
@ast
K Toth
@en
K Toth
@es
K Toth
@nl
P106
P31
P496
0000-0001-6624-9683